Literature DB >> 20425337

Is it justified to perform a bone marrow biopsy examination in sustained erythrocytosis?

Juergen Thiele1, Hans Michael Kvasnicka.   

Abstract

The diagnostic criteria of the Polycythemia Vera Study Group do not consider bone marrow histopathology, nor do they recognize the dynamics of polycythemia vera (PV). Precursor stages, when accompanied by an elevated platelet count, may clinically mimic essential thrombocythemia. Significantly extending former descriptions of bone marrow features, a trilineage myeloproliferation (panmyelosis) with a pleomorphous appearance (differences in size) of megakaryopoiesis is a characteristic histopathologic finding in PV. Differentiation from secondary polycythemia is accomplished by also considering the conspicuously expressed stromal changes (perivascular plasmacytosis, eosinophils, cell debris, and iron deposits). A clear-cut discrimination is possible, even in the initial (latent) stages of PV, which do not fulfill all the conventional diagnostic criteria. Advanced stages (spent phases) of PV show an increased left-shifted granulocytic proliferation accompanied by reduction of erythroid precursors and progressive myelofibrosis (postpolycythemic myeloid metaplasia). Finally, an increase in dysplastic changes and immaturity of cell lineages signals a transition into blastic crisis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 20425337     DOI: 10.1007/s11899-006-0028-1

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  44 in total

Review 1.  Polycythemia vera: myths, mechanisms, and management.

Authors:  Jerry L Spivak
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

2.  Development of erythrocytosis in the course of essential thrombocythemia.

Authors:  R Jantunen; E Juvonen; E Ikkala; K Oksanen; P Anttila; T Ruutu
Journal:  Ann Hematol       Date:  1999-05       Impact factor: 3.673

Review 3.  Standardization of bone marrow features--does it work in hematopathology for histological discrimination of different disease patterns?

Authors:  J Thiele; H M Kvasnicka; V Diehl
Journal:  Histol Histopathol       Date:  2005-04       Impact factor: 2.303

Review 4.  Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment.

Authors:  S Murphy; P Peterson; H Iland; J Laszlo
Journal:  Semin Hematol       Date:  1997-01       Impact factor: 3.851

Review 5.  Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders - aids to diagnosis and classification.

Authors:  J Thiele; H M Kvasnicka; R Fischer
Journal:  Ann Hematol       Date:  1999-11       Impact factor: 3.673

6.  Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification.

Authors:  T Buhr; A Georgii; H Choritz
Journal:  Pathol Res Pract       Date:  1993-03       Impact factor: 3.250

Review 7.  Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes.

Authors:  J I Dickstein; J W Vardiman
Journal:  Am J Clin Pathol       Date:  1993-04       Impact factor: 2.493

Review 8.  The bone marrow in polycythemia vera.

Authors:  J T Ellis; P Peterson
Journal:  Pathol Annu       Date:  1979

Review 9.  Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).

Authors:  Jan Jacques Michiels; Juergen Thiele
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

10.  PRV-1 mRNA expression discriminates two types of essential thrombocythemia.

Authors:  M Griesshammer; S Klippel; E Strunck; S Temerinac; U Mohr; H Heimpel; H L Pahl
Journal:  Ann Hematol       Date:  2004-03-18       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.